Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Ankylosing spondylitis (Bechterew’s disease) is a chronic inflammatory arthritis that mainly affects the spine and sacroiliac joints, causing pain, stiffness, and potential spinal fusion. Globally, its prevalence is estimated between about 0.1 % and 1.4 % of the population, disproportionately affecting males and often starting in young adulthood. According to the ankylosing spondylitis (Bechterew’s disease) pipeline analysis by Expert Market Research, the drug pipeline is expanding with novel biologics, targeted small molecules, and advanced therapies in various clinical stages, reflecting growing R&D focus. Therapies include NSAIDs, TNF and IL‑17 inhibitors, JAK inhibitors, and emerging agents aimed at improving symptom control, reducing inflammation, and enhancing mobility. The pipeline growth and rising prevalence are expected to drive market expansion and better patient outcomes in the coming years.
-
Major companies involved in the ankylosing spondylitis (bechterew’s disease) pipeline analysis include Lynk Pharmaceuticals Co., Ltd., Akeso, and others.
-
Leading drugs currently in the pipeline include LNK01001, AK111, VC005, and others.
-
The rising adoption of biologics and targeted small molecules, including IL-17, JAK, and TNF inhibitors, alongside late-stage clinical advancements and expanded indications, are strengthening therapeutic innovation and competitive pipeline expansion.
Report Coverage
The Ankylosing Spondylitis (Bechterew’s Disease) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into ankylosing spondylitis (Bechterew’s disease) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ankylosing spondylitis (Bechterew’s disease). The ankylosing spondylitis (Bechterew’s disease) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The ankylosing spondylitis (Bechterew’s disease) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with ankylosing spondylitis (Bechterew’s disease) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ankylosing spondylitis (Bechterew’s disease).
Read more about this report - Request a Free Sample
Ankylosing Spondylitis (Bechterew’s Disease) Pipeline Outlook
Ankylosing spondylitis (Bechterew’s disease) is a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and progressive loss of mobility. It occurs due to immune-mediated inflammation, strongly associated with the HLA-B27 gene, which triggers abnormal inflammatory responses that may lead to spinal fusion over time.
Ankylosing spondylitis (Bechterew’s disease) treatment includes non-steroidal anti-inflammatory drugs, biologic therapies such as tumor necrosis factor inhibitors, interleukin inhibitors, Janus kinase inhibitors, physical therapy, and lifestyle modifications to reduce inflammation and preserve mobility. In April 2022, the United States Food and Drug Administration approved upadacitinib, a Janus kinase inhibitor, for adults with active ankylosing spondylitis who had an inadequate response to Tumor Necrosis Factor blockers, expanding oral treatment options within the disease drug pipeline.
Ankylosing Spondylitis (Bechterew’s Disease) Epidemiology
The pipeline is gaining momentum due to the rising incidence and expanding patient population worldwide. According to Yuxiao Wei et al., 2025, the global incidence of Ankylosing Spondylitis ranges from 0.1% to 1.4%, typically beginning in the third decade of life, with a higher prevalence in men at a two-to-one ratio. As per Yu-Seon Jung et al., 2025, the prevalence in Korea increased from 26.76 per 100,000 individuals in 2010 to 81.87 per 100,000 in 2023, alongside a growing proportion of older and female patients. According to the Spondylitis Association of America, approximately 1.7 million adults in the United States are affected, while Rupali D et al., 2024, estimate around 1.65 million cases in India with steady annual growth.
Ankylosing Spondylitis (Bechterew’s Disease) – Pipeline Therapeutic Assessment
This section of the report covers the analysis of ankylosing spondylitis (Bechterew’s disease) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The ankylosing spondylitis (Bechterew’s disease) pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymers
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Ankylosing Spondylitis (Bechterew’s Disease) Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total ankylosing spondylitis (Bechterew’s disease) clinical trials, with 45%, reflecting strong late-stage development momentum supporting near-term commercialization. Phase II follows with 32%, indicating active mid-stage innovation. Phase IV accounts for 14%, while phase I represents 9%. Together, these phases ensure sustained market growth and therapeutic advancement.
Ankylosing Spondylitis (Bechterew’s Disease) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the ankylosing spondylitis (Bechterew’s disease) pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The ankylosing spondylitis (Bechterew’s disease) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ankylosing spondylitis (Bechterew’s disease). Biologic drug classes are gaining strong traction in the pipeline due to their targeted anti-inflammatory mechanisms. For instance, tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A, is under Phase IIb evaluation. Such immune-based therapies aim to reduce disease progression and improve long-term patient outcomes.
Ankylosing Spondylitis (Bechterew’s Disease) Clinical Trials – Key Players
The EMR report for the ankylosing spondylitis (Bechterew’s disease) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ankylosing spondylitis (Bechterew’s disease) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ankylosing spondylitis (Bechterew’s disease) clinical trials:
- Lynk Pharmaceuticals Co., Ltd.
- Akeso
- Jiangsu Vcare Pharmaceutical Technology Co., Ltd.
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
- Suzhou Zelgen Biopharmaceuticals Co., Ltd.
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Tasly Pharmaceutical Group Co., Ltd.
- UCB Biopharma SRL
- Merck Sharp & Dohme LLC
- Eli Lilly and Company
- GlaxoSmithKline
- Shanghai Junshi Bioscience Co., Ltd.
Ankylosing Spondylitis (Bechterew’s Disease) – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for ankylosing spondylitis (Bechterew’s disease). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of ankylosing spondylitis (Bechterew’s disease) drug candidates.
Drug: LNK01001
Zemprocitinib (LNK01001) is a next-generation, highly selective JAK1 inhibitor being developed by Lynk Pharmaceuticals Co., Ltd. for the treatment of active ankylosing spondylitis. The ongoing Phase 3 randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of orally administered LNK01001 taken twice daily. The objective of this phase is to examine its ability to reduce inflammation and disease activity by selectively blocking JAK1-mediated inflammatory signaling pathways. The study enrolls 352 adult patients and is continuing with a long-term open-label extension phase.
Drug: AK111
AK111 (Gumokimab) is being sponsored by Akeso in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical study for the treatment of active ankylosing spondylitis. The study examines the efficacy and safety of this investigational monoclonal antibody, which selectively targets pro-inflammatory cytokine pathways involved in chronic spinal inflammation and immune-mediated joint damage. AK111 is being administered through subcutaneous injections and is designed to modulate immune responses, reduce disease activity, and improve physical function. The objective of this phase is to confirm clinical benefit and long-term safety in a larger patient population.
Drug: VC005
VC005 Tablets is a highly selective second-generation JAK1 inhibitor being developed by Jiangsu Vcare Pharmaceutical Technology Co., Ltd. for the treatment of active Ankylosing Spondylitis. The ongoing Phase III multicenter, randomized, double-blind study is examining the efficacy and safety of orally administered VC005 Tablets compared with placebo in approximately 420 patients. The objective of this phase is to evaluate the drug’s ability to reduce inflammation, suppress immune cell activation, and improve disease symptoms while maintaining a favorable safety profile through minimized JAK2 inhibition.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Ankylosing Spondylitis (Bechterew’s Disease) Pipeline Insight Report
- Which companies/institutions are leading the ankylosing spondylitis (Bechterew’s disease) drug development?
- Which company is leading the ankylosing spondylitis (Bechterew’s disease) pipeline development activities?
- What is the current ankylosing spondylitis (Bechterew’s disease) commercial assessment?
- What are the opportunities and challenges present in the ankylosing spondylitis (Bechterew’s disease) pipeline landscape?
- What is the efficacy and safety profile of ankylosing spondylitis (Bechterew’s disease) pipeline drugs?
- Which company is conducting major trials for ankylosing spondylitis (Bechterew’s disease) drugs?
- Which companies/institutions are involved in ankylosing spondylitis (Bechterew’s disease) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in ankylosing spondylitis (Bechterew’s disease)?
Reasons To Buy This Report
The Ankylosing Spondylitis (Bechterew’s Disease) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for ankylosing spondylitis (Bechterew’s disease). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ankylosing spondylitis (Bechterew’s disease) collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share